API | muromonab cd3

muromonab cd3 (Orthoclone OKT3) Report issue

Biologics mAb Approved ^FDA

AACT ChEMBL DrugBank Drug Central KEGG MeSH

Active Ingredient History

NOW

Muromonab-CD3 is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
muromonab-cd3

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Organizations (31)

Research & Development (31)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (29)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (29)

Brain Neoplasms (Phase 2)

Carcinoma, Giant Cell (Phase 2)

Colitis, Ulcerative (Phase 1/Phase 2)

Conjunctivitis, Allergic (Phase 2)

Graft vs Host Disease (Phase 2)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1/Phase 2)

Hemoglobinuria, Paroxysmal (Phase 3)

Histiocytosis (Phase 2)

Hodgkin Disease (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 2)

Myocarditis (Phase 2)

Neoplasms (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Organ Transplantation (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 26
# of Trial Organizations: 31

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue